PROF Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of 4.04%. Profound Medical Corp.'s return on equity of -92.06% beat Delcath Systems, Inc.'s return on equity of 1.59%.

Profound Medical Corp. has a consensus price target of $12.10, signalling upside risk potential of 58.59%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.31 which suggests that it could grow by 121.72%. Given that Delcath Systems, Inc. has higher upside potential than Profound Medical Corp., analysts believe Delcath Systems, Inc. is more attractive than Profound Medical Corp..

Profound Medical Corp. has a beta of 0.569, which suggesting that the stock is 43.056% less volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.033%.

Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

Profound Medical Corp. quarterly revenues are $5.3M, which are smaller than Delcath Systems, Inc. quarterly revenues of $20.6M. Profound Medical Corp.'s net income of -$8M is lower than Delcath Systems, Inc.'s net income of $830K. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 1,156.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.47x versus 4.80x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

EXACT Sciences Corp. has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of -2.3%. Profound Medical Corp.'s return on equity of -92.06% beat EXACT Sciences Corp.'s return on equity of -38%.

Profound Medical Corp. has a consensus price target of $12.10, signalling upside risk potential of 58.59%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.69%. Given that Profound Medical Corp. has higher upside potential than EXACT Sciences Corp., analysts believe Profound Medical Corp. is more attractive than EXACT Sciences Corp..

Profound Medical Corp. has a beta of 0.569, which suggesting that the stock is 43.056% less volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

Profound Medical Corp. quarterly revenues are $5.3M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Profound Medical Corp.'s net income of -$8M is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.47x versus 6.20x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of 13.85%. Profound Medical Corp.'s return on equity of -92.06% beat Illumina, Inc.'s return on equity of 30.55%.

Profound Medical Corp. has a consensus price target of $12.10, signalling upside risk potential of 58.59%. On the other hand Illumina, Inc. has an analysts' consensus of $124.28 which suggests that it could fall by -7.79%. Given that Profound Medical Corp. has higher upside potential than Illumina, Inc., analysts believe Profound Medical Corp. is more attractive than Illumina, Inc..

Profound Medical Corp. has a beta of 0.569, which suggesting that the stock is 43.056% less volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.

Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

Profound Medical Corp. quarterly revenues are $5.3M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. Profound Medical Corp.'s net income of -$8M is lower than Illumina, Inc.'s net income of $150M. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 30.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.47x versus 4.95x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Star Operating Cos., Inc. has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of 14.56%. Profound Medical Corp.'s return on equity of -92.06% beat Star Operating Cos., Inc.'s return on equity of -3.67%.

Profound Medical Corp. has a consensus price target of $12.10, signalling upside risk potential of 58.59%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 9.59%. Given that Profound Medical Corp. has higher upside potential than Star Operating Cos., Inc., analysts believe Profound Medical Corp. is more attractive than Star Operating Cos., Inc..

Profound Medical Corp. has a beta of 0.569, which suggesting that the stock is 43.056% less volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.714, suggesting its more volatile than the S&P 500 by 171.399%.

Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Profound Medical Corp. quarterly revenues are $5.3M, which are smaller than Star Operating Cos., Inc. quarterly revenues of $23.7M. Profound Medical Corp.'s net income of -$8M is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.47x versus 0.52x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.